Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Other Accumulated Expenses (2020 - 2025)

Gain Therapeutics has reported Other Accumulated Expenses over the past 6 years, most recently at $2.3 million for Q3 2025.

  • Quarterly results put Other Accumulated Expenses at $2.3 million for Q3 2025, down 6.04% from a year ago — trailing twelve months through Sep 2025 was $2.3 million (down 6.04% YoY), and the annual figure for FY2024 was $10417.0, down 97.17%.
  • Other Accumulated Expenses for Q3 2025 was $2.3 million at Gain Therapeutics, up from $205849.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for GANX hit a ceiling of $3.5 million in Q2 2024 and a floor of $10417.0 in Q4 2024.
  • Median Other Accumulated Expenses over the past 5 years was $2.2 million (2021), compared with a mean of $1.9 million.
  • Biggest five-year swings in Other Accumulated Expenses: surged 145.31% in 2022 and later tumbled 97.17% in 2024.
  • Gain Therapeutics' Other Accumulated Expenses stood at $1.4 million in 2021, then soared by 50.2% to $2.1 million in 2022, then tumbled by 82.52% to $368345.0 in 2023, then tumbled by 97.17% to $10417.0 in 2024, then surged by 22370.03% to $2.3 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $2.3 million (Q3 2025), $205849.0 (Q2 2025), and $2.4 million (Q1 2025) per Business Quant data.